SLAM
CYTK icon

Swiss Life Asset Management’s Cytokinetics CYTK Stock Holding History

Swiss Life Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
6,728
-578
-8% -$41.5K ﹤0.01% 893
2026
Q1 		$482K Buy
7,306
+2,164
+42% +$138K ﹤0.01% 886
2025
Q4 		$327K Hold
5,142
– – ﹤0.01% 984
2025
Q3 		$283K Buy
+5,142
New +$212K ﹤0.01% 950

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Swiss Life Asset Management's CYTK Position: Q2 2026 in Review

Swiss Life Asset Management reduced its Cytokinetics (CYTK) stake by 7.9% in Q2 2026, selling an estimated $41.5K and leaving 6,728 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #893.

Swiss Life Asset Management first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 289 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Swiss Life Asset Management held 6,728 shares of Cytokinetics worth $573K as of Q2 2026.
  • Swiss Life Asset Management sold 578 Cytokinetics shares in Q2 2026, an estimated $41.5K.
  • Cytokinetics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #893 holding.
  • Swiss Life Asset Management first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 289 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.